Category Archives: Strategy

Big Data in the Pharma R&D Landscape

Big Data and the mindset that comes with it will have a fundamental impact on how pharmaceutical research will be conducted in the future, writes Peter Tormay. Innovation is the corner stone of the pharmaceutical industry. Unfortunately, the industry as a whole is not very good at it. For the last two decades the approval […]
Also posted in Guest Blog, R&D, Technology | Tagged , , | Leave a comment

The Market Will Demand a Cheaper Alternative to Sovaldi

A new report from Frost & Sullivan forecasts “robust demand” for HCV antivirals, with several strong competitors “maneuvering aggressively” to narrow the market gap by introducing a treatment that can outdo Gilead’s Sovaldi.
Also posted in healthcare, pricing | Tagged , , , | Leave a comment

New "Blockbusters" Will Triple Acute Coronary Syndrome Market

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
Also posted in Global | Tagged , , , , , , , | Leave a comment

Pharm Exec's 2014 Dealmakers Outlook

After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up. Pharm Exec brought partner Campbell Alliance and a select group of West Coast […]
Also posted in Deals, Global | Tagged , , , | Leave a comment

Shire Takeover "Could Save AbbVie $8 Billion Tax on Humira over Next 15 Years"

AbbVie’s recent $54 billion acquisition of Shire and subsequent relocation to Ireland will mean substantial tax savings for the US pharmaceutical giant, according to analysts at research and consulting firm GlobalData.
Also posted in Deals, Europe, Global | Tagged , , , , | Leave a comment
  • Categories

  • Meta